ClinicalTrials.gg
TerminatedNCT02189551LOKOMATUpdated Aug 15, 2018

Advanced Robotic Training With Additional Degrees of Freedom: Towards a Free-walking System

An interventional study of Gait training with Lokomat Pro and Gait training with Lokomat Pro FreeD in Post Stroke Gait Training, sponsored by Cereneo AG. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by Cereneo AG · Not applicable, Interventional, and Health services research

How we know

Why this study was terminated
an additional intervention, amendet to the study (3rd arm, not described here), has not received clearance by regulatory authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 216 studies in Stroke with a site in Switzerland — 46 open to participants now, 60 under way, 6 of them phase 3. Stroke · Switzerland.

Enrollment
143rd of 147
9 · median 79
Started
2014
with 14 others
No phase
95 of 216
24 open now
Registered
57th of 216
by date
Lead sponsor
6 of 216
Cereneo AG

Among the 216 studies in Stroke with a site in Switzerland, this one is the 143rd largest by enrollment of the 147 interventional ones that give a count, is one of 15 that started in 2014, is one of 95 with no phase, and was the 57th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

46 of the 216 studies in Stroke with a site in Switzerland are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Stroke with a site in Switzerland, or all of them as a file.
02

Study summary

The objective of the study is to compare a new medical devices with an established medical device for lower limb rehabilitation regarding training outcome and patient comfort / patient satisfaction (primary objective) and treatment effect (exploratory objective).

Primary study endpoints will be a significantly higher rated patient comfort and or patient satisfaction using the new versions, compared with the established Lokomat. Furthermore, muscle activity and kinematic movement patterns will be expected to show more involved muscle groups and a walking pattern involving more degrees of freedom during use of the new version compared with the established Lokomat.

Exploratory endpoints will be a significantly stronger involvement of muscles needed for balance, more physiological walking patterns and more change on the lateral positioning of the feet due to training with the new version, compared with the established Lokomat.

03

Conditions studied

  • Post Stroke Gait Training

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lower extremity weakness due to stroke
  • minor functional impairment (MRC \< 5)
  • ability and willingness to participate

Exclusion criteria

Exclusion Criteria:

  • severe spasticity of the lower extremities
  • severe dementia
  • severe depression
  • any other against Lokomat training
  • body weight > 135 kg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    Lokomat Pro

    gait robot established on the market

    Behavioral: Gait training with Lokomat Pro

  • Experimental
    Lokomat Pro FreeD

    gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market

    Behavioral: Gait training with Lokomat Pro FreeD

Interventions

  • BehavioralGait training with Lokomat Pro
  • BehavioralGait training with Lokomat Pro FreeD
06

What researchers measure

Primary outcomes

  1. Lateral hip movement

    during 30 min training with each device, lateral hip movements will be assessed

    Time frame: 30 min training during day 1 (next session after inclusion)

Secondary outcomes

  1. Patient satisfaction

    Satisfaction, based on questionnaires, will be assessed after training with the experimental and the standard device in two consecutive sessions (randomized order).

    Time frame: day 2 and 3

  2. Patient motivation

    Patient motivation, based on questionnaires, will be assessed after training with the experimental and the standard device in two consecutive sessions (randomized order).

    Time frame: day 2 and 3

07

Study locations

1 site
  • Cereneo, Center For Rehabilitation and Neurology
    Vitznau, LU 6354, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2014
First posted
Jul 14, 2014
Start
Jun 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02189551
Lead sponsor
Cereneo AG
Collaborators
Swiss Commission for Technology and Innovation, Swiss Federal Institute of Technology, Hocoma AG, University of Zurich
Responsible party
Sponsor
First posted
Jul 14, 2014
Start date
Jun 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Aug 15, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion